Slate Therapeutics

Company Overview

Snapshot

Founded in April 2021 by Dr. Eitan, Gary Binyamin, Tanhum Feld, and Eran Vickus, Slate Therapeutics operates with 1–10 employees. The company has raised $1 million across one funding round from two investors. In January 2022, Slate Therapeutics secured pre-seed funding from NGT HealthCare II and Israel Innovation Authority.

Business overview

Slate Therapeutics is a Health Tech & Life Sciences company focused on revolutionizing the treatment of chronic rhinosinusitis (CRS). The company's core product, SilexGel, is a novel sol-gel hydrogel technology designed for the systemic and localized delivery of therapeutics. This cutting-edge platform aims to provide long-lasting effects with minimal side effects, serving the healthcare and medical devices industries, with a particular focus on patients.

Company Intelligence Q&A

What is Slate Therapeutics' primary focus?

Slate Therapeutics is dedicated to revolutionizing the treatment of chronic rhinosinusitis (CRS) through its innovative SilexGel technology.

When was Slate Therapeutics founded and by whom?

Slate Therapeutics was founded in April 2021 by Dr. Eitan, Gary Binyamin, Tanhum Feld, and Eran Vickus.

What is SilexGel?

SilexGel is Slate Therapeutics' cutting-edge platform technology, a novel sol-gel hydrogel designed for the systemic and localized delivery of therapeutics, aiming to provide long-lasting effects with minimal side effects.

What is the company's mission?

Slate Therapeutics' mission is to improve the quality of life for patients through innovative and effective treatments for chronic rhinosinusitis (CRS).

Which sectors does Slate Therapeutics operate in?

Slate Therapeutics operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology, Drug Delivery, and Drugs Discovery & Development.